Pancreatic cancer is a highly aggressive malignancy with a mortality rate above 98%. Currently the only curative therapy for pancreatic cancer is surgical resection. Due to late disease detection, this is only suitable for about 20% of all patients. Therapeutic options for locally advanced or metastatic pancreatic cancer are therefore needed. Importantly, for pancreatic cancer there is no good standard of care after a first chemotherapy (in average 11 month after diagnosis), and thus the hurdle to test experimental compounds is very low.